UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 16, 2001
MEDITECH PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-12561 95-3819300
(State or other (Commission (I.R.S. Employer
jurisdiction File Number) Identification No.)
of incorporation)
10105 E. Via Linda, #103, PMB 382
Phoenix, Arizona 85258
(Address of principal executive office, including zip code)
(480) 614-2874
(Registrant's telephone number, including area code)
ITEM 4. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT
On July 16, 2001, Meditech Pharmaceuticals, Inc. (the "Company") dismissed
Singer Lewak Greenbaum & Goldstein, LLP as its independent auditor. Singer Lewak
Greenbaum & Goldstein, LLP's audit reports on the Company's financial statements
for the years ended May 31, 2000, 1999 and 1998 were included in the Company's
Form 10-K, which was filed on August 8, 2000. None of the audit reports
contained an adverse opinion or disclaimer of opinion; however, the audit
reports for such periods did contain a going concern qualification. The decision
to dismiss Singer Lewak Greenbaum & Goldstein, LLP was approved by the Company's
Board of Directors.
Management of the Company knows of no past disagreements between the
Company and Singer Lewak Greenbaum & Goldstein, LLP on any matter of accounting
principles or practices, financial statement disclosure or auditing scope or
procedure. There were no "reportable events" (as such term is defined in Item
304 of Regulation S-K) that occurred within the Company's two most recent fiscal
years nor any subsequent interim period preceding the replacement of Singer
Lewak Greenbaum & Goldstein, LLP.
On July 17, 2001, the Company engaged Corbin & Wertz, which appointment was
approved by the Company's Board of Directors. During the Company's two most
recent fiscal years and any subsequent interim period prior to the engagement of
Corbin & Wertz, neither the Company nor anyone on the Company's behalf consulted
with Corbin & Wertz regarding either (i) the application of accounting
principles to a specified transaction, either contemplated or proposed, or the
type of audit opinion that might be rendered on the Company's financial
statements or (ii) any matter that was either the subject of a "disagreement" or
a "reportable event."
The Company has authorized Singer Lewak Greenbaum & Goldstein, LLP to
respond fully to all inquiries of Corbin & Wertz.
The Company has provided Singer Lewak Greenbaum & Goldstein, LLP with a
copy of the disclosures being made in this Form 8-K and has requested that they
furnish a letter to the Company addressed to the Securities and Exchange
Commission stating whether it agrees with the above statements.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(a) Financial Statements - None
(b) Exhibits - None
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDITECH PHARMACEUTICALS, INC.
Date: July 23, 2001 By: /s/ GERALD N. KERN
---------------------------------
Gerald N. Kern
Chief Executive Officer